ValuentumAd

Official PayPal Seal

Amgen Posts Mixed Third-Quarter Results, Sales of Epogene Nosedive

publication date: Oct 24, 2011
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Amgen's third-quarter results were mixed, as revenue and earnings growth was overshadowed by a legal charge and weakness with Epogene. We think the company looks cheap, but are waiting cautiously for improvement in its score on our Valuentum Buying Index.


Subscribe Now to Gain Access!

This page is available to subscribers only. To gain access to members only content (including this research piece), click here to subscribe. With a subscription, you'll have access to all of our premium commentary, equity reports, dividend reports and Best Ideas Newsletter and Dividend Growth Newsletter, as well as receive discounts on all of our modeling tools and products. Financial advisers and institutional investors have even more to choose from!

Click to Learn More about Valuentum

If you are already a subscriber, please login.

If you believe you should be able to view this area then please contact us and we will try to rectify this issue as soon as possible.


To gain access to the members only content, click here to subscribe. You will be given immediate access to premium content on the site.